➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
AstraZeneca
Colorcon
Merck
Johnson and Johnson

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 8,583,380

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 8,583,380
Title:Methods for stratifying and annotating cancer drug treatment options
Abstract: Personalized medicine involves the use of a patient\'s molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
Inventor(s): Stephan; Dietrich (San Francisco, CA), Norviel; Vern (San Jose, CA), Warrington; Janet (Los Altos, CA), Dolginow; Doug (Potomac, MD)
Assignee: Aueon, Inc. (Menlo Park, CA)
Application Number:13/060,425
Patent Claims:see list of patent claims

Details for Patent 8,583,380

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 2006-09-27 ⤷  Free Forever Trial Aueon, Inc. (Menlo Park, CA) 2028-09-05 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 2004-02-26 ⤷  Free Forever Trial Aueon, Inc. (Menlo Park, CA) 2028-09-05 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 2004-06-18 ⤷  Free Forever Trial Aueon, Inc. (Menlo Park, CA) 2028-09-05 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,583,380

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2010028288 ⤷  Free Forever Trial
United States of America 2011230360 ⤷  Free Forever Trial
United States of America 2014080733 ⤷  Free Forever Trial
United States of America 2014141426 ⤷  Free Forever Trial
United States of America 2014141980 ⤷  Free Forever Trial
United States of America 2016115553 ⤷  Free Forever Trial
United States of America 2016115554 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Harvard Business School
Moodys
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.